Inupadenant

Inupadenant is an orally active, highly selective A2A receptor antagonist. Inupadenant can not cross BBB. Inupadenant can enhance the humoral immune response and has anti-tumor activity[1][2].

Product Specifications

CAS Number

[2246607-08-7]

Product Name Alternative

EOS-850

UNSPSC

12352005

Target

Adenosine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/inupadenant.html

Purity

98.27

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

O=C1SC(C2=NC(C3=CC=CO3)=NN2C(N)=N4)=C4N1CCN5CCN(C(C(F)=C6)=CC(OCC[S@](C)=O)=C6F)CC5

Molecular Formula

C25H26F2N8O4S2

Molecular Weight

604.65

References & Citations

[1]Laurence Buisseret, et al. Phase 1 trial of the adenosine A2Areceptor antagonist inupadenant (EOS-850) : Update on tolerability, and antitumor activity potentially associated with the expression of the A2A receptor within the tumor. Journal of Clinical Oncology. Volume 39, Issue 15_suppl.|[2]Tieppo P, et al. 48P The A2AR antagonist inupadenant promotes humoral responses in preclinical models. Immuno-Oncology and Technology, 2024, 24.